E
Eric Siemers
Researcher at Eli Lilly and Company
Publications - 153
Citations - 24600
Eric Siemers is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Solanezumab & Dementia. The author has an hindex of 44, co-authored 145 publications receiving 19862 citations. Previous affiliations of Eric Siemers include Indiana University.
Papers
More filters
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack,David A. Bennett,Kaj Blennow,Maria C. Carrillo,Billy Dunn,Samantha Budd Haeberlein,David M. Holtzman,William J. Jagust,Frank Jessen,Jason Karlawish,Enchi Liu,José Luis Molinuevo,Thomas J. Montine,Creighton H. Phelps,Katherine P. Rankin,Christopher C. Rowe,Philip Scheltens,Eric Siemers,Heather M. Snyder,Reisa A. Sperling,Cerise L Elliott,Eliezer Masliah,Laurie M. Ryan,Nina Silverberg +23 more
TL;DR: This research framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms and envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD.
Journal ArticleDOI
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw,Hugo Vanderstichele,Malgorzata Knapik-Czajka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam J. Simon,Piotr Lewczuk,Robert A. Dean,Eric Siemers,William Z. Potter,Virginia M.-Y. Lee,John Q. Trojanowski +14 more
TL;DR: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Journal ArticleDOI
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody,Ronald G. Thomas,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Rema Raman,Xiaoying Sun,Paul S. Aisen,Eric Siemers,Hong Liu-Seifert,Richard C. Mohs +12 more
TL;DR: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with mild Alzheimer's disease.
Journal ArticleDOI
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Rachelle S. Doody,Rema Raman,Martin R. Farlow,Takeshi Iwatsubo,Bruno Vellas,Steven Joffe,Karl Kieburtz,Feng He,Xiaoying Sun,Ronald G. Thomas,Paul S. Aisen,Eric Siemers,Gopalan Sethuraman,Richard C. Mohs +13 more
TL;DR: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability, and semagACestat was associated with more adverse events, including skin cancers and infections.